Recent changes in the incidence of prostate cancer in the United States are stunning and
unprecedented in magnitude. From 1989 to 1991 alone, age-adjusted incidence increased …

Objectives. The use of prostate-specific antigen (PSA) to screen for prostate cancer remains
controversial. Although it is still too early to measure directly the effects of PSA screening on …

Objective. The purpose of this study was to compare prostate cancer incidence and mortality
trends between the United States and Canada over a period of approximately 30 years …

Screening and treatment for prostate cancer is controversial. In the absence of randomized
trials, several prominent medical organizations in the United States and Europe have …

PURPOSE: We describe trends in prostate cancer mortality from 1980 to 1997, before and
after the introduction of serum prostate specific antigen (PSA) testing to the community …

The increased use of prostate-specific antigen (PSA) in screening for preclinical disease
after 1985 is thought to be a major determinant of the changing patterns in prostate cancer …

Objectives: The purpose of this study was to describe changes in the incidence of prostate
cancer and in survival of diagnosed cases, as well as prostate cancer-specific mortality …

Screening for prostate cancer with serum prostate specific antigen (PSA) is one of the most
controversial practices in health care today and guidelines from professional and policy …

Background Prostate cancer is a significant public health issue in the United States. It is the
most commonly diagnosed non-skin cancer and the second leading cause of cancer death …

Objective To quantify the plausible contribution of prostate-specific antigen (PSA) screening
to the nearly 30% decline in the US prostate cancer mortality rate observed during the …